Skip to main content

Table 1 Patients baseline demographics and disease characteristics

From: Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors

Characteristic Selinexor 60 mg QW/BIW  +  carboplatin 6 AUC Q3W (N  = 6) Selinexor 60 mg QW/BIW  +  doxorubicin 60 mg/m2  +  cyclophosphamide 600 mg/m2 Q3W (N  = 4) Selinexor 40 mg QW  +  FOLFIRIa (N  = 3) Selinexor 60 mg QW  + irinotecan 125 mg/m2 D1 and 8 Q3W (N  = 3) Selinexor 40 mg QW  +  XELOXb (N  = 3) All patients (N  = 19)
Age at consent (years)
 Median range 56.1 (31.2–76.1) 61.7 (23.6–64.9) 49.9 (38.1–70.7) 67.8 (57.9–72.3) 65.9 (51.8–72.8) 60.6 (23.6–76.1)
Gender, N (%)
 Male 1 (17) 2 (50) 1 (33) 1 (33) 2 (67) 7 (37)
 Female 5 (83) 2 (50) 2 (67) 2 (67) 1 (33) 12 (63)
Race/ethnicity, N (%)
 White 4 (67) 4 (100) 3 (100) 1 (33) 3 (100) 15 (79)
 Hispanic 0 0 0 0 0 0
 Black 1 (17) 0 0 1 (33) 0 2 (11)
 Asian 1 (17) 0 0 1 (33) 0 2 (11)
ECOG performance status, N (%)
 0 1 (17) 0 1 (33) 2 (67) 1 (33) 5 (26)
 1 5 (83) 4 (100) 2 (67) 1 (33) 2 (67) 14 (74)
Primary tumor, N (%)
 Ovarian 0 2 (50) 0 0 0 2 (11)
 Breast 3 (50) 0 0 0 0 3 (16)
 Colorectal cancer 0 0 1 (33) 1 (33) 1 (33) 3 (16)
 Endometrial/fallopian 0 0 0 0 0 0
 Lung 1 (17) 0 0 0 0 1 (5)
 Neuroendocrine 0 0 1 (33) 1 (33) 0 2 (11)
 Pancreas 0 0 1 (33) 0 1 (33) 2 (11)
 Esophageal 0 0 0 0 0 0
 Head and neck/salivary gland 1 (17) 0 0 1 (33) 0 2 (11)
 Liver/cholangiocarcinoma 0 0 0 0 1 (33) 1 (5)
 Sarcoma 0 1 (25) 0 0 0 1 (5)
 Prostate 0 1 (25) 0 0 0 1 (5)
 Others 1 (17) 0 0 0 0 1 (5)
Prior lines of systemic therapies, N (%)
 0–1 1 (17) 0 0 0 0 1 (5)
 2–3 4 (67) 3 (75) 2 (67) 2 (67) 2 (67) 13 (68)
 4–5 1 (17) 1 (25) 1 (33) 0 1 (33) 4 (21)
 > 5 0 0 0 1 (33) 0 1 (5)
 Median range 2.5 (1.0–4.0) 2.0 (2.0–4.0) 3.0 (3.0–5.0) 3.0 (2.0–6.0) 3.0 (2.0–4.0) 3.0 (1.0–6.0)
  1. N number; ECOG Eastern Cooperative Oncology Group; QW once weekly; BIW twice weekly; AUC area under curve; mg/m2 milligrams per square meter; D1 and 8 on days 1, and 8 of each cycle; Q3W every 3 week; FOLFIRI irinotecan with fluorouracil and folinic acid; XELOX capecitabine and oxaliplatin
  2. aFOLFIRI—irinotecan of 180 mg/m2, 5-FU continuous infusion of 2400 mg/m2, 5-FU bolus of 400 mg/m2, and leucovorin of 400 mg/m2 on days 1, and 15
  3. bXELOX—capecitabine was dosed at 900 mg/m2 orally (PO) divided into 2 doses on days 1–14, along with oxaliplatin of 130 mg/m2 IV Q3W